SCHEMBL5583897

SCHEMBL5583897

O=S(=O)([O-])CCCOc1ccc(OCCCS(=O)(=O)[O-])cc1.[Na+].[Na+]

nearest known ligand 0.48

Known targets — ChEMBL curated mechanism

ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 known ✓ O43570 6/20 0.48
CA1 known ✓ P00915 6/20 0.48
CA2 known ✓ P00918 6/20 0.48
CA4 known ✓ P22748 3/20 0.42
CA9 Q16790 6/20 0.48
CA7 P43166 3/20 0.48
TSHR P16473 3/20 0.48
MAPK1 P28482 2/20 0.43
GMNN O75496 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
THPO P40225 1/20 0.43
HBB P68871 1/20 0.43
PMP22 Q01453 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PABPC1 P11940 1/20 0.42
EIF4H Q15056 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
MGLL Q99685 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5583895 0.94 MGLL (0.47) CA12CA1CA2CA9CA7
SCHEMBL5583945 0.91 MEN1 (0.48) CA12CA1CA2CA9CA7
SCHEMBL7220133 0.91 CA12 (0.45) CA12CA1CA2CA9CA7
SCHEMBL28347602 0.90 KCNA3 (0.56) CA12CA1CA2CA9CA7
SCHEMBL12468573 0.89 CA12 (0.46) CA12CA1CA2CA9CA7
SCHEMBL11505191 0.86 ALDH1A1 (0.60) TSHRALDH1A1SMN1; SMN2
Potassium Ion SCHEMBL10575515 0.86 KCNA3 (0.56) CA12CA1CA2CA9CA7
SCHEMBL19282554 0.85 TDP1 (0.44) CA12CA1CA2CA9CA7
SCHEMBL1172038 0.84 KCNA3 (0.59) ALDH1A1PABPC1EIF4HCTDSP1MGLL
SCHEMBL10012742 0.83 CYP19A1 (0.50) TSHRTP53PABPC1EIF4HCTDSP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9956229-B2 Acyclic cucurbit[n]uril type molecular containers to treat intoxication and decrease relapse rate in substance abuse disorders UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2018-05-01 US disclosed
US-20170246180-A1 ACYCLIC CUCURBIT[N]URIL TYPE MOLECULAR CONTAINERS TO TREAT INTOXICATION AND DECREASE RELAPSE RATE IN SUBSTANCE ABUSE DISORDERS GENERAL HOSPITAL CORPORATION 2017-08-31 US disclosed
EP-2627641-A1 REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK USING NOVEL MOLECULAR CONTAINERS University of Maryland, College Park (US) 2013-08-21 EP disclosed
EP-2627657-A2 MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME University of Maryland, College Park (US) 2013-08-21 EP disclosed
WO-2012051407-A2 MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2012-04-19 WO disclosed
WO-2012051413-A1 REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK USING NOVEL MOLECULAR CONTAINERS UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2012-04-19 WO disclosed
US-7279244-B2 Fuel cell, polyelectrolyte and ion-exchange resin use for same HITACHI, LTD. (JP) 2007-10-09 US disclosed
US-7022743-B2 Fuel cell, polyelectrolyte and ion-exchange resin used for same HITACHI, LTD. (JP) 2006-04-04 US disclosed
US-6989212-B2 Fuel cell, polyelectrolyte and ion-exchange resin used for same HITACHI, LTD. (JP) 2006-01-24 US disclosed
US-20050271923-A1 Fuel cell, polyelectrolyte and ion-exchange resin use for same HITACHI, LTD. (JP) 2005-12-08 US disclosed
US-20030129467-A1 Fuel cell, polyelectrolyte and ion-exchange resin used for same HITACHI, LTD. (JP) 2003-07-10 US disclosed
US-20030118886-A1 Fuel cell, polyelectrolyte and ion-exchange resin used for same HITACHI, LTD. (JP) 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170246180-A1 ACYCLIC CUCURBIT[N]URIL TYPE MOLECULAR CONTAINERS TO TREAT INTOXICATION AND DECREASE RELAPSE RATE IN SUBSTANCE ABUSE DISORDERS CNR1, CNR2, OPRM1 CA12 1284/4885CA1 974/4885CA2 1123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.